person · Reporting owner

Horning Sandra

Disclosed activity across 5 companies

Tapewire entity: 14722
SEC CIK: 0001638709

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
GILEAD SCIENCES, INC.GILD · Entity 405	Director	April 30, 2026	May 04, 2026
Moderna, Inc.MRNA · Entity 2025	Director	May 06, 2026	May 08, 2026
Olema Pharmaceuticals, Inc.OLMA · Entity 613	Director	June 18, 2026	June 23, 2026
Revolution Medicines, Inc.RVMD · Entity 606	Director	June 18, 2026	June 23, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

GILEAD SCIENCES, INC.

Report date April 30, 2026 · Filed May 04, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	6,293	Reported balance After 2026-04-30 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-04-30 · Grant · Acquired 1,146 · Balance 6,293 F1: Represents 1,146 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of April 30, 2026.
Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $130.84 · Expires 2036-04-30	Direct	4,884	Reported balance After 2026-04-30 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-04-30 · Grant · Acquired 4,884 · Balance 4,884 F2: 100% of the shares subject to the stock option vested immediately upon the grant date of April 30, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: Represents 1,146 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of April 30, 2026.

F2: 100% of the shares subject to the stock option vested immediately upon the grant date of April 30, 2026.

Moderna, Inc.

Report date May 06, 2026 · Filed May 08, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $48.79 · Expires 2036-05-06	Direct	9,681	Reported balance After 2026-05-06 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-05-06 · Grant · Acquired 9,681 · Balance 9,681 F1: This option will become fully vested and exercisable on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	2,092	Reported balance After 2026-05-06 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-05-06 · Grant · Acquired 2,092 · Balance 2,092 F2: Restricted stock units convert into common stock on a one-for-one basis. F3: The shares subject to this restricted stock unit award will vest in full on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service.

Filing footnotes · ownership attribution and instrument terms

F1: This option will become fully vested and exercisable on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service.

F2: Restricted stock units convert into common stock on a one-for-one basis.

F3: The shares subject to this restricted stock unit award will vest in full on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service.

Olema Pharmaceuticals, Inc.

Report date June 18, 2026 · Filed June 23, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.51 · Expires 2036-06-18	Direct	29,500	Reported balance After 2026-06-18 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-18 · Grant · Acquired 29,500 · Balance 29,500 F1: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 18, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 18, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

Revolution Medicines, Inc.

Report date June 18, 2026 · Filed June 23, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	97,765	Reported balance After 2026-06-18 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-06-18 · Grant · Acquired 1,191 · Balance 97,765 F1: Includes 6,083 restricted stock units.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $162.99 · Expires 2036-06-18	Direct	3,127	Reported balance After 2026-06-18 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-18 · Grant · Acquired 3,127 · Balance 3,127 F2: Shares subject to the Option shall vest in full on the earlier of (i) the first anniversary of June 18, 2026 or (ii) immediately prior to the Annual Meeting following the date of grant subject to the Reporting Person remaining a Service Provider (as defined in the 2020 Plan) through the vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Includes 6,083 restricted stock units.

F2: Shares subject to the Option shall vest in full on the earlier of (i) the first anniversary of June 18, 2026 or (ii) immediately prior to the Annual Meeting following the date of grant subject to the Reporting Person remaining a Service Provider (as defined in the 2020 Plan) through the vesting date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

EQRx, Inc.

Report date November 09, 2023 · Filed November 09, 2023

Section 16 reporting ended · disclosed 2023-11-09. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2023-11-09 transaction · row 1 1 source row Row 1 · 2023-11-09 · Disposition to issuer · Disposed 470,250 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger dated July 31, 2023 (the "Merger Agreement"), by and among the Issuer, Revolution Medicines, Inc. ("Revolution Medicines"), Equinox Merger Sub, Inc., a direct, wholly owned subsidiary of Revolution Medicines ("Merger Sub I"), and Equinox Merger Sub II LLC, a direct, wholly owned subsidiary of Revolution Medicines ("Merger Sub II"), pursuant to which Merger Sub I merged with and into the Issuer effective as of November 9, 2023 (the "Effective Time"), with the Issuer surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines (the "First Merger"), and promptly after the First Merger, the Issuer merged with and into Merger Sub II, with Merger Sub II surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines. F2: At the Effective Time, each share of Issuer common stock that was issued and outstanding immediately prior to the Effective Time was converted into the right to receive a number of validly issued, fully paid and non-assessable shares of Revolution Medicines common stock equal to 0.1112 (the "Exchange Ratio") and cash in lieu of any fractional shares of Revolution Medicines common stock any former holder of Issuer common stock would otherwise be entitled to receive, without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.44 · Expires 2030-08-21	Direct	Reported balance After 2023-11-09 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-11-09 · Disposition to issuer · Disposed 313,500 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger dated July 31, 2023 (the "Merger Agreement"), by and among the Issuer, Revolution Medicines, Inc. ("Revolution Medicines"), Equinox Merger Sub, Inc., a direct, wholly owned subsidiary of Revolution Medicines ("Merger Sub I"), and Equinox Merger Sub II LLC, a direct, wholly owned subsidiary of Revolution Medicines ("Merger Sub II"), pursuant to which Merger Sub I merged with and into the Issuer effective as of November 9, 2023 (the "Effective Time"), with the Issuer surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines (the "First Merger"), and promptly after the First Merger, the Issuer merged with and into Merger Sub II, with Merger Sub II surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines. F3: Pursuant to the Merger Agreement, each Issuer stock option that was outstanding and unexercised became fully vested and exercisable as of immediately prior to the Effective Time. F4: At the Effective Time, each Issuer stock option that was outstanding immediately prior to the Effective Time and had an exercise price per share less than $2.16 (an "In-the-Money Option") was cancelled and converted automatically into the right to receive a number of shares of Revolution Medicines common stock equal to the quotient of (i) the product of (a) the number of shares of Issuer common stock subject to the In-the-Money Option immediately prior to the Effective Time, multiplied by (b) the excess of $2.16 over the exercise price of such In-the-Money Option, divided by (ii) $19.4690, less the number of shares of Revolution Medicines common stock having a fair market value as of the Effective Time equal to the amount necessary to satisfy the award holder's tax withholding obligations. (All Issuer stock options that did not constitute In-the-Money Options were terminated at the Effective Time for no consideration).
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.95 · Expires 2032-09-30	Direct	Reported balance After 2023-11-09 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-11-09 · Disposition to issuer · Disposed 101,010 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger dated July 31, 2023 (the "Merger Agreement"), by and among the Issuer, Revolution Medicines, Inc. ("Revolution Medicines"), Equinox Merger Sub, Inc., a direct, wholly owned subsidiary of Revolution Medicines ("Merger Sub I"), and Equinox Merger Sub II LLC, a direct, wholly owned subsidiary of Revolution Medicines ("Merger Sub II"), pursuant to which Merger Sub I merged with and into the Issuer effective as of November 9, 2023 (the "Effective Time"), with the Issuer surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines (the "First Merger"), and promptly after the First Merger, the Issuer merged with and into Merger Sub II, with Merger Sub II surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines. F3: Pursuant to the Merger Agreement, each Issuer stock option that was outstanding and unexercised became fully vested and exercisable as of immediately prior to the Effective Time. F4: At the Effective Time, each Issuer stock option that was outstanding immediately prior to the Effective Time and had an exercise price per share less than $2.16 (an "In-the-Money Option") was cancelled and converted automatically into the right to receive a number of shares of Revolution Medicines common stock equal to the quotient of (i) the product of (a) the number of shares of Issuer common stock subject to the In-the-Money Option immediately prior to the Effective Time, multiplied by (b) the excess of $2.16 over the exercise price of such In-the-Money Option, divided by (ii) $19.4690, less the number of shares of Revolution Medicines common stock having a fair market value as of the Effective Time equal to the amount necessary to satisfy the award holder's tax withholding obligations. (All Issuer stock options that did not constitute In-the-Money Options were terminated at the Effective Time for no consideration).
Earn-out SharesSEC Table II · derivative / convertible security · Expires 2024-12-17	Direct	Reported balance After 2023-11-09 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-11-09 · Disposition to issuer · Disposed 107,929 · Balance 0 F5: Pursuant to the terms of the Agreement and Plan of Merger dated August 5, 2021 (the "DeSPAC Merger Agreement"), by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.), the Reporting Person was allocated the right to acquire an aggregate of 107,929 shares of Issuer common stock (the "Earn-out Shares"), (i) 75,550 of which will be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 32,379 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. F6: Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment pursuant to the terms of the DeSPAC Merger Agreement. F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger dated July 31, 2023 (the "Merger Agreement"), by and among the Issuer, Revolution Medicines, Inc. ("Revolution Medicines"), Equinox Merger Sub, Inc., a direct, wholly owned subsidiary of Revolution Medicines ("Merger Sub I"), and Equinox Merger Sub II LLC, a direct, wholly owned subsidiary of Revolution Medicines ("Merger Sub II"), pursuant to which Merger Sub I merged with and into the Issuer effective as of November 9, 2023 (the "Effective Time"), with the Issuer surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines (the "First Merger"), and promptly after the First Merger, the Issuer merged with and into Merger Sub II, with Merger Sub II surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines. F2: At the Effective Time, each share of Issuer common stock that was issued and outstanding immediately prior to the Effective Time was converted into the right to receive a number of validly issued, fully paid and non-assessable shares of Revolution Medicines common stock equal to 0.1112 (the "Exchange Ratio") and cash in lieu of any fractional shares of Revolution Medicines common stock any former holder of Issuer common stock would otherwise be entitled to receive, without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement. F7: Each share of Issuer common stock that was issued and outstanding immediately prior to the Effective Time and held in escrow subject to the earn-out on the terms and subject to the conditions of the DeSPAC Merger Agreement was converted in the same manner as all other shares of Issuer common stock under the Merger Agreement.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger dated July 31, 2023 (the "Merger Agreement"), by and among the Issuer, Revolution Medicines, Inc. ("Revolution Medicines"), Equinox Merger Sub, Inc., a direct, wholly owned subsidiary of Revolution Medicines ("Merger Sub I"), and Equinox Merger Sub II LLC, a direct, wholly owned subsidiary of Revolution Medicines ("Merger Sub II"), pursuant to which Merger Sub I merged with and into the Issuer effective as of November 9, 2023 (the "Effective Time"), with the Issuer surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines (the "First Merger"), and promptly after the First Merger, the Issuer merged with and into Merger Sub II, with Merger Sub II surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines.

F2: At the Effective Time, each share of Issuer common stock that was issued and outstanding immediately prior to the Effective Time was converted into the right to receive a number of validly issued, fully paid and non-assessable shares of Revolution Medicines common stock equal to 0.1112 (the "Exchange Ratio") and cash in lieu of any fractional shares of Revolution Medicines common stock any former holder of Issuer common stock would otherwise be entitled to receive, without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement.

F3: Pursuant to the Merger Agreement, each Issuer stock option that was outstanding and unexercised became fully vested and exercisable as of immediately prior to the Effective Time.

F4: At the Effective Time, each Issuer stock option that was outstanding immediately prior to the Effective Time and had an exercise price per share less than $2.16 (an "In-the-Money Option") was cancelled and converted automatically into the right to receive a number of shares of Revolution Medicines common stock equal to the quotient of (i) the product of (a) the number of shares of Issuer common stock subject to the In-the-Money Option immediately prior to the Effective Time, multiplied by (b) the excess of $2.16 over the exercise price of such In-the-Money Option, divided by (ii) $19.4690, less the number of shares of Revolution Medicines common stock having a fair market value as of the Effective Time equal to the amount necessary to satisfy the award holder's tax withholding obligations. (All Issuer stock options that did not constitute In-the-Money Options were terminated at the Effective Time for no consideration).

F5: Pursuant to the terms of the Agreement and Plan of Merger dated August 5, 2021 (the "DeSPAC Merger Agreement"), by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.), the Reporting Person was allocated the right to acquire an aggregate of 107,929 shares of Issuer common stock (the "Earn-out Shares"), (i) 75,550 of which will be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 32,379 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50.

F6: Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment pursuant to the terms of the DeSPAC Merger Agreement.

F7: Each share of Issuer common stock that was issued and outstanding immediately prior to the Effective Time and held in escrow subject to the earn-out on the terms and subject to the conditions of the DeSPAC Merger Agreement was converted in the same manner as all other shares of Issuer common stock under the Merger Agreement.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
April 28, 2022 Filed May 2, 2022 20:38 UTC	Moderna, Inc. MRNA · Entity 2025	GrantStock Option (Right to Buy) · Derivative	4,061	$0.00 Strike: $142.52	$0.00	Disclosure SEC source: 0001127602-22-012854 · form4.xml · derivative · entry 3 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,061 Underlying: Common Stock · 4,061 shares Expires not disclosed F3 · derivative.exercise_date: This option will become fully vested and exercisable on the earlier of April 28, 2023, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service. F3 · derivative.expiration_date: This option will become fully vested and exercisable on the earlier of April 28, 2023, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service. Read SEC document
April 28, 2022 Filed May 2, 2022 20:38 UTC	Moderna, Inc. MRNA · Entity 2025	Exercise / conversionRestricted Stock Units · Derivative	703	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001127602-22-012854 · form4.xml · derivative · entry 2 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 703 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: The shares subject to this restricted stock unit award vested in full on April 28, 2022. F2 · derivative.expiration_date: The shares subject to this restricted stock unit award vested in full on April 28, 2022. Read SEC document
April 28, 2022 Filed May 2, 2022 20:38 UTC	Moderna, Inc. MRNA · Entity 2025	Exercise / conversionCommon Stock	703	$0.00	$0.00	Disclosure SEC source: 0001127602-22-012854 · form4.xml · nonDerivative · entry 1 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 703 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document
December 17, 2021 Filed Dec 21, 2021 06:30 UTC	EQRx, Inc. EQRX · Entity 108311	GrantEarn-out Shares · Derivative	107,364	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-21-049126 · doc4.xml · derivative · entry 3 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,364 Underlying: Common Stock · 107,364 shares Expires 2024-12-17 F3 · derivative.exercise_price: Upon consummation of the Business Combination, the Reporting Person received the right to acquire 107,364 shares of the Issuer's Common Stock (the "Earn-out Shares"), (i) 75,155 of which will be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 32,209 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment per the terms of the Merger Agreement. F3 · kind: Upon consummation of the Business Combination, the Reporting Person received the right to acquire 107,364 shares of the Issuer's Common Stock (the "Earn-out Shares"), (i) 75,155 of which will be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 32,209 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment per the terms of the Merger Agreement. F3 · price: Upon consummation of the Business Combination, the Reporting Person received the right to acquire 107,364 shares of the Issuer's Common Stock (the "Earn-out Shares"), (i) 75,155 of which will be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 32,209 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment per the terms of the Merger Agreement. F3 · derivative.exercise_date: Upon consummation of the Business Combination, the Reporting Person received the right to acquire 107,364 shares of the Issuer's Common Stock (the "Earn-out Shares"), (i) 75,155 of which will be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 32,209 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment per the terms of the Merger Agreement. Read SEC document
December 17, 2021 Filed Dec 21, 2021 06:30 UTC	EQRx, Inc. EQRX · Entity 108311	GrantStock Option (Right to Buy) · Derivative	313,500	$0.00 Strike: $0.44	$0.00	Disclosure SEC source: 0000899243-21-049126 · doc4.xml · derivative · entry 2 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,500 Underlying: Common Stock · 313,500 shares Expires 2030-08-21 F2 · kind: These options were issued under the Legacy EQRx 2019 Stock Option and Grant Plan (the "2019 Plan") and were assumed in the Business Combination pursuant to the terms of the Merger Agreement and the 2019 Plan and are now exercisable for shares of the Issuer's Common Stock. The shares underlying this option vest and become exercisable in 16 equal quarterly installments commencing August 21, 2020, subject to the Reporting Person's continuous service as of each vesting date. F2 · derivative.exercise_date: These options were issued under the Legacy EQRx 2019 Stock Option and Grant Plan (the "2019 Plan") and were assumed in the Business Combination pursuant to the terms of the Merger Agreement and the 2019 Plan and are now exercisable for shares of the Issuer's Common Stock. The shares underlying this option vest and become exercisable in 16 equal quarterly installments commencing August 21, 2020, subject to the Reporting Person's continuous service as of each vesting date. Read SEC document
December 17, 2021 Filed Dec 21, 2021 06:30 UTC	EQRx, Inc. EQRX · Entity 108311	GrantCommon Stock	470,250	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-21-049126 · doc4.xml · nonDerivative · entry 1 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 470,250 F1 · kind: On December 17, 2021, upon consummation of the transactions (the "Closing" of the "Business Combination") contemplated by the Agreement and Plan of Merger dated August 5, 2021 (the "Merger Agreement") by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc., "Legacy EQRx"), each share of Legacy EQRx capital stock was exchanged, pursuant to the Merger Agreement, for shares of the Issuer's Common Stock. F1 · price: On December 17, 2021, upon consummation of the transactions (the "Closing" of the "Business Combination") contemplated by the Agreement and Plan of Merger dated August 5, 2021 (the "Merger Agreement") by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc., "Legacy EQRx"), each share of Legacy EQRx capital stock was exchanged, pursuant to the Merger Agreement, for shares of the Issuer's Common Stock. Read SEC document
June 09, 2021 Filed Jun 10, 2021 22:39 UTC	Olema Pharmaceuticals, Inc. OLMA · Entity 613	GrantStock Option (right to buy) · Derivative	21,520	$0.00 Strike: $27.66	$0.00	Disclosure SEC source: 0001415889-21-002927 · form4-06102021_030608.xml · derivative · entry 1 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,520 Underlying: Common Stock · 21,520 shares Expires 2031-06-08 F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 9, 2021, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date. Read SEC document
May 12, 2021 Filed May 14, 2021 20:15 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	GrantNon-qualified Stock Option (Right to Buy) · Derivative	14,665	$0.00 Strike: $67.45	$0.00	Disclosure SEC source: 0001127602-21-016827 · form4.xml · derivative · entry 2 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,665 Underlying: Common Stock · 14,665 shares Expires 2031-05-12 F3 · derivative.exercise_date: 25% of the shares subject to the option vest on each three-month anniversary from May 12, 2021 such that 100% of the shares subject to the option will be fully vested and exercisable upon the earlier of May 12, 2022 or the day immediately preceding the next regular annual stockholders meeting. Read SEC document
May 12, 2021 Filed May 14, 2021 20:15 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	GrantRestricted Stock Unit · Derivative	2,223	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-21-016827 · form4.xml · derivative · entry 1 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,159 Underlying: Common Stock · 2,223 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences Inc.'s common stock. F2 · derivative.exercise_date: 100% of the restricted stock units will vest on the earlier of May 12, 2022 or the day immediately preceding the next regular annual stockholders meeting. F2 · derivative.expiration_date: 100% of the restricted stock units will vest on the earlier of May 12, 2022 or the day immediately preceding the next regular annual stockholders meeting. Read SEC document
April 28, 2021 Filed Apr 30, 2021 20:09 UTC	Moderna, Inc. MRNA · Entity 2025	GrantRestricted Stock Units · Derivative	703	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001127602-21-014772 · form4.xml · derivative · entry 2 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 703 Underlying: Common Stock · 703 shares Expires not disclosed F2 · derivative.exercise_date: The shares subject to this restricted stock unit award will vest in full on the earlier of April 28, 2022, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service. F2 · derivative.expiration_date: The shares subject to this restricted stock unit award will vest in full on the earlier of April 28, 2022, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service. Read SEC document
April 28, 2021 Filed Apr 30, 2021 20:09 UTC	Moderna, Inc. MRNA · Entity 2025	GrantStock Option (Right to Buy) · Derivative	4,081	$0.00 Strike: $178.68	$0.00	Disclosure SEC source: 0001127602-21-014772 · form4.xml · derivative · entry 1 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,081 Underlying: Common Stock · 4,081 shares Expires 2031-04-28 F1 · derivative.exercise_date: This option will become fully vested and exercisable on the earlier of April 28, 2022, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service. Read SEC document
January 28, 2021 Filed Jan 29, 2021 22:46 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	Exercise / conversionRestricted Stock Unit · Derivative	632	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-21-003029 · form4.xml · derivative · entry 2 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,936 Underlying: Common Stock · 632 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences Inc.'s common stock. F2 · derivative.exercise_date: 100% of the restricted stock units vested on January 28, 2021. F2 · derivative.expiration_date: 100% of the restricted stock units vested on January 28, 2021. Read SEC document
January 28, 2021 Filed Jan 29, 2021 22:46 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	Exercise / conversionCommon Stock	632	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-21-003029 · form4.xml · nonDerivative · entry 1 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 632 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences Inc.'s common stock. Read SEC document
November 18, 2020 Filed Nov 19, 2020 23:44 UTC	Olema Pharmaceuticals, Inc. OLMA · Entity 613	GrantStock Option (Right to Buy) · Derivative	86,083	$0.00 Strike: $19.00	$0.00	Disclosure SEC source: 0001209191-20-059514 · doc4.xml · derivative · entry 1 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,083 Underlying: Common Stock · 86,083 shares Expires 2030-11-17 F1 · derivative.exercise_date: The shares subject to the option vest in a series of 36 successive equal monthy installments measured from November 18, 2020, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document
May 06, 2020 Filed May 7, 2020 23:39 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	GrantNon-qualified Stock Option (Right to Buy) · Derivative	7,886	$0.00 Strike: $77.47	$0.00	Disclosure SEC source: 0001127602-20-015831 · form4.xml · derivative · entry 2 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,886 Underlying: Common Stock · 7,886 shares Expires 2030-05-06 F3 · derivative.exercise_date: 25% of the shares subject to the option vest on each three-month anniversary measured from May 6, 2020 such that 100% of the shares subject to the option will be fully vested and exercisable upon the earlier of May 6, 2021 or the day immediately preceding the next regular annual stockholders meeting. Read SEC document
May 06, 2020 Filed May 7, 2020 23:39 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	GrantRestricted Stock Unit · Derivative	1,936	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-20-015831 · form4.xml · derivative · entry 1 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,568 Underlying: Common Stock · 1,936 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences Inc.'s common stock. F2 · derivative.exercise_date: 100% of the restricted stock units will vest on the earlier of May 6, 2021, or the day immediately preceding the next regular annual stockholders meeting. F2 · derivative.expiration_date: 100% of the restricted stock units will vest on the earlier of May 6, 2021, or the day immediately preceding the next regular annual stockholders meeting. Read SEC document
April 29, 2020 Filed May 1, 2020 22:21 UTC	Moderna, Inc. MRNA · Entity 2025	GrantStock Option (Right to Buy) · Derivative	18,270	$0.00 Strike: $46.37	$0.00	Disclosure SEC source: 0001127602-20-015097 · form4.xml · derivative · entry 2 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,270 Underlying: Common Stock · 18,270 shares Expires 2030-04-29 F2 · derivative.exercise_date: This option will become fully vested and exercisable on the earlier of April 29, 2021, or the next Annual Meeting of Stockholders, subject to the recipient's continued service. Read SEC document
April 29, 2020 Filed May 1, 2020 22:21 UTC	Moderna, Inc. MRNA · Entity 2025	GrantStock Option (Right to Buy) · Derivative	17,195	$0.00 Strike: $46.37	$0.00	Disclosure SEC source: 0001127602-20-015097 · form4.xml · derivative · entry 1 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,195 Underlying: Common Stock · 17,195 shares Expires 2030-04-29 F1 · derivative.exercise_date: This option will be fully vested and exercisable on April 29, 2021. Read SEC document
January 28, 2020 Filed Jan 30, 2020 21:29 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	GrantRestricted Stock Unit · Derivative	632	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-20-002759 · form4.xml · derivative · entry 2 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 632 Underlying: Common Stock · 632 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences Inc.'s common stock. F2 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences Inc.'s common stock. F3 · derivative.exercise_date: 100% of the restricted stock units will vest on January 28, 2021. F3 · derivative.expiration_date: 100% of the restricted stock units will vest on January 28, 2021. Read SEC document
January 28, 2020 Filed Jan 30, 2020 21:29 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	GrantNon-qualified Stock Option (Right to Buy) · Derivative	3,837	$0.00 Strike: $64.36	$0.00	Disclosure SEC source: 0001127602-20-002759 · form4.xml · derivative · entry 1 Horning Sandra · CIK 0001638709 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,837 Underlying: Common Stock · 3,837 shares Expires 2030-01-28 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on each three-month anniversary measured from January 28, 2020 such that 100% of the shares subject to the option will be fully vested and exercisable on January 28, 2021. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.